Latest Conference Articles

Amicus presented additional positive results from the company’s Phase 1/2 clinical study of ATB200/AT2221 in patients with Pompe disease in a late-breaker poster and a corresponding oral presentation.

Today at the WORLDSymposium in San Diego, Valerion Therapeutics presented initial results from the first cohort of its ongoing Phase 1/2 clinical study of VAL-1221 in patients with late-onset Pompe disease.

At the 14th Annual WORLDSymposium, interim data from two open-label studies were presented, exhibiting a 3-year survival estimate of 68% in infants with rapidly progressing LAL-D treated with sebelipase alfa.

The potential glaucoma and dry eye device administers 80% less topical treatment per dose.

The distractive spots floating through fields of vision may have finally met their match.

The multi-targeted inhibitor, a non-invasive eye drop, acts in a different way of treating the chronic disease.

The diagnostics of the disease is not only important for the initial evaluation, but also etiology and long-term management.

A review of over 13,000 newly-diagnosed DME patients found that about 75% received no treatment in the first 28 days since diagnosis.

Vision loss patients may be 3 times as likely to suffer from major depressive symptoms than the general population.

Attendees at MS Paris 2017 discussed the biggest unmet needs in treating multiple sclerosis.

Two consecutive CHEST studies showed combination therapy's expanding portfolio.

Telemedicine is more than just a trend in medicine – it's one of the most potent tools available to health systems and patients alike.

There's a perfect storm brewing that makes telemedicine an inevitability in the management of conditions like asthma and COPD.

After implementing a team-based care approach to COPD, one hospital saved $600 per patient, per year.

Teriflunomide was an effective first-line therapy for RRMS and a suitable switch therapy in real-world data.

The TOPIC study results additionally showed a strong association between CGMV loss and CDMS conversion.

Tanuja Chitnis, MD, spoke about the first-of-its-kind PARADIGMS trial, and pediatric multiple sclerosis, as well as how it differs from the condition in adults.

Subgroup analysis revealed a greater improvement for patients with baseline visual impairment.

Alemtuzumab showed significant reductions in MRI lesions and slowed brain volume loss in 5-year results for RRMS.

Martin Weber, MD, spoke about the role that B cells and antibodies play in the treatment of multiple sclerosis.

The UN and WHO aim to reduce the burden of cholera globally by 90% reduction in deaths by 2030.

Learn more about the decrease in yellow fever vaccine production that will last until mid-2018.

Why is delafloxacin unique compared to other fluoroquinolones? Find out more.

As drug costs continue to rise, many are hoping generics will bring relief. But will they?

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the future for HIV drug prices.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about challenges of Hepatitis C treatment.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the hottest topic in infectious disease.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, talks about treatment options for Candida auris and multi-drug resistant treatment options.